Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Kedar Eli

Researchers

Last updated December 2021 -  Immunology and Cancer Research

List of Publications

(1) Hemed-Shaked M, Cowman MK, Kim JR, Huang X, Chau E, Ovadia H, et al. MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A. J Autoimmun 2021;124.

(2) Even-or O, Samira S, Ellis R, Kedar E, Barenholz Y. Adjuvanted influenza vaccines. Expert Rev Vaccines 2013;12(9):1095-1108.

(3) Even-Or O, Joseph A, Itskovitz-Cooper N, Samira S, Rochlin E, Eliyahu H, et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity. Vaccine 2011;29(13):2474-2486.

(4) Zeira E, Manevitch A, Manevitch Z, Kedar E, Gropp M, Daudi N, et al. Femtosecond laser: A new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization. FASEB J 2007;21(13):3522-3533.

(5) Mitchell LA, Joseph A, Kedar E, Barenholz Y, Galun E. Mucosal immunization against hepatitis A: Antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid. Vaccine 2006;24(25):5300-5310.

(6) Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). I. Immunogenicity and efficacy studies in mice. Vaccine 2006;24(18):3990-4006.

(7) Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen-Gross T, Katz G, et al. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 2004;103(2):664-672.

(8) Achdout H, Arnon TI, Markel G, Gonen-Gross T, Katz G, Lieberman N, et al. Enhanced recognition of human NK receptors after influenza virus infection. J Immunol 2003;171(2):915-923.

(9) Ben-Yehuda A, Joseph A, Barenholz Y, Zeira E, Even-Chen S, Louria-Hayon I, et al. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. Vaccine 2003;21(23):3169-3178.

(10) Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J Med Virol 2003;69(4):560-567.

(11) Joseph A, Louria-Hayon I, Plis-Finarov A, Zeira E, Zakay-Rones Z, Raz E, et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): An efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002;20(27-28):3342-3354.

(12) Babai I, Barenholz Y, Zakay-Rones Z, Greenbaum E, Samira S, Hayon I, et al. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine 2001;20(3-4):505-515.

(13) Van Slooten ML, Hayon I, Babai I, Zakay-Rones Z, Wagner E, Storm G, et al. Immunoadjuvant activity of interferon-γ-liposomes co-administered with influenza vaccines. Biochim Biophys Acta Mol Cell Biol Lipids 2001;1531(1-2):99-110.

(14) Van Slooten ML, Boerman O, Romøren K, Kedar E, Crommelin DJA, Storm G. Liposomes as sustained release system for human interferon-γ: Biopharmaceutical aspects. Biochim Biophys Acta Mol Cell Biol Lipids 2001;1530(2-3):134-145.

(15) Kedar E, Gur H, Babai I, Samira S, Even-Chen S, Barenholz Y. Delivery of cytokines by liposomes: Hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long- circulating liposomes. J Immunother 2000;23(1):131-145.

(16) Kedar E, Gur H, Babai I, Samira S, Even-Chen S, Barenholz Y. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. J Immunother 2000;23(1):4759.

(17) Leshem B, Dorfman Y, Kedar E. Induction of preferential cytotoxicity against allogeneic mouse lymphoma cells: In vitro and in vivo studies. Cancer Immunol Immunother 1999;48(4):179-188.

(18) Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. Vaccine 1999;17(9-10):1239-1250.

(19) Babai I, Samira S, Barenholz Y, Zakay-Rones Z, Kedar E. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine 1999;17(9-10):1223-1238.

(20) Cabanes A, Even-Chen S, Zimberoff J, Barenholz Y, Kedar E, Gabizon A. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Clin Canc Res 1999;5(3):687-693.

(21) Bishara A, Malka R, Brautbar C, Barak V, Cohen I, Kedar E. Cytokine production in human mixed leukocyte reactions performed in serum-free media. J Immunol Methods 1998;215(1-2):187-190.

(22) Kedar E, Palgi O, Golod G, Babai I, Barenholz Y. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-α show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother 1997;20(3):180-193.

(23) Leshem B, Brass D, Kedar E. Lose of lymphoblast immunogenicity and susceptibility to specific ctl lysis following their maintenance in culture. FASEB J 1996;10(6).

(24) Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: Pharmacokinetics and biodistribution in tumor-bearing mice. Pharm Res 1996;13(6):861-868.

(25) Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y. Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes. Pharm Res 1996;13(3):352-359.

(26) Gazit Z, Kedar E. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice. Cancer Immunol Immunother 1994;38(4):243-252.

(27) Bishara A, Brautbar C, Nagler A, Slavin S, Leshem B, Cohen I, et al. Prediction by a modified mixed leukocyte reaction assay of graft-versus-host disease and graft rejection after allogeneic bone marrow transplantation. Transplantation 1994;57(10):1474.

(28) Kedar E, Rutkowski Y, Braun E, Emanuel N, Barenholz Y. Delivery of Cytokines by Liposomes. I. Preparation and Characterization of Interleukin-2 Encapsulated in Long-Circulating Sterically Stabilized Liposomes. J Immunother 1994;16(1):47-59.

(29) Kedar E, Braun E, Rutkowski Y, Emanuel N, Barenholz Y. Delivery of Cytokines by Liposomes. II. Interleukin-2 Encapsulated in Long-Circulating Sterically Stabilized Liposomes: Immunomodulatory and Anti-Tumor Activity in Mice. J Immunother 1994;16(2):115-124.

(30) Bishara A, Kedar E, Leshem B, Slavin S, Cohen I, Brautbar C. A 2‐DAY MLR PROCEDURE FOR MARROW DONOR SELECTION FOR ALLOGENEIC BONE MARROW TRANSPLANTATION. Int J Immunogenet 1993;20(4):289-292.

(31) Gazit Z, Weiss DW, Shouval D, Yechezkeli M, Schirrmacher V, Notter M, et al. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines. Cancer Immunol Immunother 1992;35(2):135-144.

(32) Leshem B, Dekel R, Bercovier H, Tchakirov R, Polacheck I, Zakay-Rones Z, et al. Cytokine-induced resistance to microbial infections in normal, immunosuppressed and bone marrow transplanted mice. Bone Marrow Transplant 1992;9(6):471-477.

(33) Isacson R, Kedar E, Barak V, Gazit Z, Yurim O, Kalichman I, et al. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with decarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response. Immunol Lett 1992;33(2):127-134.

(34) Beilin B, Shavit Y, Cohn S, Kedar E. Narcotic-induced suppression of natural killer cell activity in ventilated and nonventilated rats. Clin Immunol Immunopathol 1992;64(2):173-176.

(35) Kedar E, Klein E. Cancer immunotherapy: Are the results discouraging? Can they be improved? Adv Cancer Res 1992;59(C):245-322.

(36) Kedar E, Rutkowski Y, Leshem B. Chemo-Immunotherapy of murine solid tumors: Enhanced therapeutic effects by interleukin-2 combined with interferon α and the role of specific T cells. Cancer Immunol Immunother 1992;35(1):63-68.

(37) Klein E, Kedar E, Wang P, Vanky F. Recognition of transformed cells by autologous lymphocytes: A review. In Vivo 1991;5(6):625-630.

(38) Ackerstein A, Kedar E, Slavin S. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood 1991;78(5):1212-1215.

(39) Slavin S, Ackerstein A, Kedar E, Reich S, Gomez S, Naparstek E, et al. Induction of cell-mediated IL-2-activated antitumor responses in conjunction with autologous and allogeneic bone marrow transplantation. Transplant Proc 1991;23(1 I):802-803.

(40) Bishara A, Kedar E, Leshem B, Rosenkovitch E, Brautbar C. A short human and mouse mlr assay utilizing lymphokine (Il-2, il-3) secretion as an early activation event. Transplantation 1991;51(5):1104-1109.

(41) Tamir M, Eren R, Globerson A, Kedar E, Epstein E, Trainin N, et al. Selective accumulation of lymphocyte precursor cells mediated by stromal cells of hemopoietic origin. Exp Hematol 1990;18(4):332-340.

(42) Leshem B, Kedar E. Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization. J Exp Med 1990;171(4):1057-1071.

(43) Slavin S, Ackerstein A, Kedar E, Weiss L. IL-2 activated cell-mediated immunotherapy: Control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2. Bone Marrow Transplant 1990;6(SUPPL. 1):86-89.

(44) Kedar E, Ben-Aziz R, Epstein E, Leshem B. Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide - IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type. Cancer Immunol Immunother 1989;29(1):74-78.

(45) Leshem B, Epstein E, Kedar E. Allosensitization in IL-2-containing limiting dilution cultures generates cytotoxic T lymphocytes (CTL) rather than LAK cells reactive with a syngeneic nonimmunogenic murine tumor. Immunol Lett 1989;20(1):53-58.

(46) Slavin S, Mumcuoglu M, Landesberg-Weisz A, Kedar E. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z). Bone Marrow Transplant 1989;4(5):459-464.

(47) Kedar E, Ben-Aziz R, Shiloni E. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells. Isr J Med Sci 1988;24(9-10):494-504.

(48) Leshem B, Cohen I, Sherman L, Brautbar C, Kedar E. Typing of HLA class II and class I antigens using PHA-activated, IL-2-propagated T lymphocytes. J Immunol Methods 1988;111(1):131-135.

(49) Resnick M, Roguel N, Bercovier H, Enk C, Frankenburg S, Kedar E. Lysis of murine macrophages infected with intracellular pathogens by interleukin 2-activated killer (LAK) cells in vitro. Cell Immunol 1988;113(1):214-219.

(50) Slavin S, Kedar E. Current problems and future goals in clinical bone marrow transplantation. Blood Rev 1988;2(4):259-269.

(51) Kedar E, Or R, Naparstek E, Zeira E, Slavin S. Preliminary characterization of functional residual host-type I lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT). Bone Marrow Transplant 1988;3(2):129-140.

(52) Kedar E, Rezai AR, Giorgi JV, Gale RP, Champlin RE, Mitsuyasu RT, et al. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells. Nat Immun Cell Growth Regul 1988;7(1):13-30.

(53) Kedar E, Tsuberi B-, Landesberg A, Anafi M, Leshem B, Gillis S, et al. In vitro and in vivo cytokine-induced facilitation of immunohematopoietic reconstitution in mice undergoing bone marrow transplantation. Bone Marrow Transplant 1988;3(4):297-314.

(54) Leshem B, Lebendiker Z, Weiss L, Slavin S, Kedar E. Suppressor T cells in allogeneic bone marrow chimeras. Bone Marrow Transplant 1987;2(2):123-132.

(55) Tsuberi B, Slavin S, Kedar E, Leshem B. Transfer of B memory cells to a T-dependent antigen in murine bone marrow transplantation. Transplant Proc 1987;19(1 Pt 3):2747-2749.

(56) Leshem B, Tsuberi B-, Lebendiker Z, Anafi-Ayalon M, Shalit M, Weiss L, et al. Bone marrow transplantation with T-cell-depleted grafts: II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens. Transplantation 1987;43(6):814-817.

(57) Kedar E, Zeira E, Lebendiker Z, Weiss DW, Katan R, Shouval D. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies. Prog Clin Biol Res 1987;244:59-75.

(58) Kedar E, Bercowitz H, Katz-Gross A, Chriqui-Zeira E. Stimulatory and suppressive effects of anti-cancer drugs and x-irradiation on the production of interleukin-2 by murine lymphoid cells. Immunopharmacology 1986;11(1):61-65.

(59) Mann V, Szyf M, Razin A, Chriqui‐Zeira E, Kedar E. Characterization of a tumorigenic murine T‐lymphoid‐cell line spontaneously derived from an IL‐2‐dependent T‐cell line. Int J Cancer 1986;37(5):781-786.

(60) Shalit M, Ayalon M, Weiss L, Leshem B, Kedar E, Slavin S. Bone marrow transplantation with t–cell–depleted grafts: I. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted syngeneic bone marrow grafts. Transplantation 1986;42(2):118-122.

(61) Szyf M, Kaplan F, Mann V, Giloh H, Kedar E, Razin A. Cell cycle-dependent regulation of eukaryotic DNA methylase level. J Biol Chem 1985;260(15):8653-8656.

(62) Leshem B, Gotsman B, Lebendiker Z, Kedar E. Induction of cytotoxic response against syngeneic weakly immunogenic murine tumors by in vitro allosensitization. Transplant Proc 1985;17(1 II):896-899.

(63) Yefenof E, Feinmani R, Kedar E. Antigen non-specific activities in culture supernatant of ovalbumin-specific, cloned helper T lymphoma. Immunobiology 1985;169(5):520-531.

(64) Kedar E, Chriqui-Zeira E, Mitelman S. Methods for amplifying the induction and expression of cytotoxic response in vitro to syngeneic and autologous freshly-isolated solid tumors of mice. Cancer Immunol Immunother 1984;18(2):126-134.

(65) Leshem B, Gotsman B, Kedar E. In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization. Cancer Immunol Immunother 1984;17(2):117-123.

(66) Kedar E, Chriqui-Zeira E. Chemoimmunotherapy of carcinomas in mice using lymphokines and IL-2-propagated lymphocytes. Fed Proc 1984;43(6).

(67) Adler A, Stein JA, Kedar E, Naor D, Weiss DW. Intralesional injection of interleukin-2 — Expanded autologous lymphocytes in melanoma and breast cancer patients: A pilot study. J Biol Response Modif 1984;3(5):491-500.

(68) Kedar E, Katz-Gross A, Chriqui-Zeira E, Bercowitz H. Suppression by tumor growth of T cell growth factor production in mouse lymphoid cell cultures. J Biol Response Modif 1984;3(5):547-560.

(69) Leshem B, Kedar E. In vitro elicitation of cytotoxic response against a syngeneic nonimmunogenic murine tumor. Fed Proc 1984;43(6).

(70) Kedar E, Chriqui-Zeira E, Kyriazis AP. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes. J Biol Response Modif 1984;3(5):517-526.

(71) Ginsburg H, Ben-David E, Kinarty A, Rofolovitch M, Amitay M, Chriqui E, et al. Murine interleukin-2 generates glycogen-rich and mucus-secreting NK cells. Immunology 1983;49(4):571-583.

(72) Kedar E, Weiss DW. The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy. Adv Cancer Res 1983;38(C):171-287.

(73) Kedar E, Bercowitz H. Effect of tumor growth, anti-neoplastic drugs and irradiation on the production of IL-2 in mice. Fed Proc 1983;42(3).

(74) Kedar E, Ikejiri BL, Timonen T, Bonnard GD, Reid J, Navarro NJ, et al. Antitumor reactivity in vitro and in vivo of lymphocytes from normal donors and cancer patients propagated in culture with T cell growth factor (TCGF). Eur J Cancer Clin Oncol 1983;19(6):757-763,765-773.

(75) Kedar E, Ikejiri BL, Gorelik E, Herbermann RB. Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF). Cancer Immunol Immunother 1982;13(1):14-23.

(76) Kedar E, Ikejiri BL, Sredni B, Bonavida B, Herberman RB. Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cell Immunol 1982;69(2):305-329.

(77) Kedar E, Ikejiri BL, Bonnard GD, Herberman RB. A rapid technique for isolation of viable tumor cells from solid tumors: Use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses. Eur J Cancer Clin Oncol 1982;18(10):991-1000.

(78) Kedar E, Schwartzbach M, Klein E. Expression of H-2b alloantigens in a variant of a moloney virus-induced YAC (H-2a) lymphoma. Eur J Cancer Clin Oncol 1982;18(9):861-865.

(79) Weiss L, Kedar E, Weigensberg M, Slavin S. Natural cell-mediated cytotoxicity in mice treated with total lymphoid irradiation (TLI). Cell Immunol 1982;70(1):188-195.

(80) Azar Y, Eidelsztein P, Yefenof E, Chriqui E, Katz-Gross A, Kedar E, et al. Antigen-specific murine T-cell lymphomas: Functional heterogenicity. Cell Immunol 1981;65(1):194-200.

(81) Gorelik E, Kedar E, Sredni B, Herberman R. In vivo anti‐tumor effects of local adoptive transfer of mouse and human cultured lymphoid cells. Int J Cancer 1981;28(2):157-164.

(82) Yefenof E, Meidav A, Kedar E. In vitro generation of cytotoxic lymphocytes against radiation- and radiation leukemia virus-induced tumors: III. Suppression of anti-tumor immunity in vitro by lymphocytes of mice undergoing radiation leukemia virus-induced leukemogenesis. J Exp Med 1980;152(6):1473-1483.

(83) Kedar E, Avraham Y. Amplification by hydrocortisone of the induction of cytotoxic response in vitro to syngeneic murine leukemias. Transplantation 1980;29(2):169-171.

(84) Yefenof E, Tchakirov R, Kedar E. In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus-induced tumors - I. Role of viral antigenicity. Cancer Immunol Immunother 1980;8(2-3):171-178.

(85) Kedar E, Raanan Z, Kafka I, Holland JF, Bekesi GJ, Weiss DW. In vitro induction of cytotoxic effector cells against human neoplasms. I. Sensitization conditions and effect of cryopreservation on the induction and expression of cytotoxic responses to allogeneic leukemia cells. J Immunol Methods 1979;28(3-4):303-319.

(86) Kedar E, Lupu T, Schwartzbach M, Avraham Y. In vitro induction of cell-mediated immunity to murine leukemia cells. VII. Methods for augmenting the induction and expression of cytotoxic response in vitro to syngeneic tumors. J Immunol Methods 1979;26(2):157-171.

(87) Kedar E, Schwartzbach M. Further characterization of suppressor lymphocytes induced by fetal calf serum in murine lymphoid cell cultures: Comparison with in vitro-generated cytotoxic lymphocytes. Cell Immunol 1979;43(2):326-340.

(88) Devens B, Naor D, Kedar E. Immune response to weakly immunogenic virally induced tumors iv dissociated recognition of H-2 and tumor associated antigens: IV dissociated recognition of h 2 and tumor associated antig4ens. Transplantation 1979;28(5):389-395.

(89) Kedar E, Schwartzbach M, Unger E, Lupu T. Characteristics of suppressor cells induced by fetal bovine serum in murine lymphoid cell cultures. Transplantation 1978;26(1):63-65.

(90) Kedar E, Clark WR, Bonavida B. In vivo and in vitro induction of cytotoxic lymphocytes by alloantigen-reactive lymphocytes fractionated on spleen cell monolayers. Transplantation 1978;25(3):146-151.

(91) Kedar E, Raanan Z, Schwartzbach M. In vitro induction of cell-mediated immunity to murine leukemia cells - VI. Adoptive immunotherapy in combination with chemotherapy of leukemia in mice, using lymphocytes sensitized in vitro to leukemia cells. Cancer Immunol Immunother 1978;4(3):161-169.

(92) Kedar E, Lupu T. In vitro induction of cell-mediated immunity to murine leukemia cells. IV. amplification of the generation of cytotoxic lymphocytes by enzymatically and chemically modified stimulator leukemic cells. J Immunol Methods 1978;21(1-2):35-50.

(93) Kedar E, Nahas F, Unger E, Weiss DW. In Vitro Induction of Cell-Mediated Immunity to Murine Leukemia Cells. III. Effect of Methanol Extraction Residue Fraction of BCG on the Generation of Cytotoxic Lymphocytes Against Leukemia. J Natl Cancer Inst 1978;60(5):1097-1106.

(94) Kedar E, Schwartzbach M, Hefetz S, Raanan Z. In vitro induction of cell-mediated immunity to murine leukemia cells - V. Adoptive immunotherapy of leukemia in mice with lymphocytes sensitized in vitro to leukemia cells. Cancer Immunol Immunother 1978;4(3):151-159.

(95) Bonavida B, Grimm E, Kedar E. Frequency of thymus-dependent plaque-forming units: direct estimation by a modified plaque assay. Transplant Proc 1977;9(1):705-708.

(96) Kedar E, Schwartzbach M, Raanan Z. Adoptive immunotherapy of murine leukemia with lymphoid cells sensitized in vitro to leukemic cells. Isr J Med Sci 1977;13(10):1063.

(97) Kedar E, Schwartzbach M, Raanan Z, Hefetz S. In vitro induction of cell-mediated immunity to murine leukemia cells. II. Cytotoxic activity in vitro and tumor-neutralizing capacity in vivo of anti-leukemia cytotoxic lymphocytes generated in macrocultures. J Immunol Methods 1977;16(1):39-58.

(98) Bonavida B, Ikejiri B, Kedar E. Direct estimation of frequency of cytotoxic T lymphocytes by a modified plaque assay. Nature 1976;263(5580):769-771.

(99) Kedar E, Unger E, Galili N, Klein G, Asjo B, Bonavida B, et al. Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS). Prog Clin Biol Res 1976;9:109-121.

(100) Zighelboim J, Gale RP, Kedar E. Polymorphonuclear leukocyte Fc receptors in antibody‐dependent cellular cytotoxicity (ADCC). Transplantation 1976;21(6):524-526.

(101) Kedar E, Unger E, Schwartzbach M. In vitro induction of cell-mediated immunity to murine leukemia cells. I. Optimization of tissue culture conditions for the generation of cytotoxic lymphocytes. J Immunol Methods 1976;13(1):1-19.

(102) Weiss DW, Kuperman O, Fathallah N, Kedar E. MODE OF ACTION OF MYCOBACTERIAL FRACTIONS IN ANTITUMOR IMMUNITY: PRELIMINARY EVIDENCE FOR A DIRECT NONSPECIFIC STIMULATORY EFFECT OF MER ON IMMUNOLOGICALLY REACTIVE CELLS. Ann New York Acad Sci 1976;276(1):536-549.

(103) Schroit AJ, Kedar E, Gallily R. A rapid and sensitive technique for the detection of Fc receptors on macrophages. J Immunol Methods 1976;12(1-2):163-170.

(104) Kedar E, Bonavida B. Studies on the induction and expression of T cell mediated immunity. IV. Non overlapping populations of alloimmune cytotoxic lymphocytes with specificity for tumor associated antigens and transplantation antigens. J Immunol 1975;115(5):1301-1308.

(105) De Landazuri MO, Kedar E, Fahey JL. Synergism between cytotoxic cells and immune serum in a syngeneic lymphoma: characterization of two types of cytotoxic cells. Behring Inst Mitt 1975;no. 56:3-14.

(106) Bonavida B, Kedar E. Transplantation of allogeneic lymphoid cells specifically depleted of graft versus host reactive cells. Nature 1974;249(5458):658-659.

(107) Kedar E, Bonavida B. Studies on the induction and expression of T cell mediated immunity. III. Amplification by papain of the generation of cytotoxic lymphocytes to allogeneic cells. J Immunol 1974;113(4):1386-1389.

(108) Ortiz De Landazuri M, Kedar E, Fahey JL. Synergistic cooperation between isoantiserum and immune lymphoid cells: in vitro studies with a syngeneic rat lymphoma. J Immunol 1974;112(6):2102-2110.

(109) Kedar E, Bonavida B. Histamine receptor bearing leukocytes (HRL). I. Detection of histamine receptor bearing cells by rosette formation with histamine coated erythrocytes. J Immunol 1974;113(5):1544-1552.

(110) Kedar E, Ortiz de Landazuri M, Bonavida B, Fahey JL. Cellular immunoadsorbents. An improved technique for specific depletion of cytotoxic (T) lymphoid cells. J Immunol Methods 1974;5(1):97-102.

(111) de Landazuri MO, Kedar E, Fahey JL. Simultaneous expression of cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity to a syngeneic rat lymphoma: Separation and partial characterization of two types of cytotoxic cells. Cell Immunol 1974;14(2):193-205.

(112) Kedar E, Ortiz De Landazuri M, Fahey JL. Comparative studies of immunoglobulin receptors and antibody dependent cell cytotoxicity (ADCC) in rat lymphoid organs. J Immunol 1974;112(1):37-46.

(113) Kedar E, Ortiz De Landazuri M, Bonavida B. Cellular immunoadsorbents: a simplified technique for separation of lymphoid cell populations. J Immunol 1974;112(3):1231-1243.

(114) Kedar E, Ortiz De Landazuri M, Fahey JL. Enzymatic enhancement of cell mediated cytotoxicity and antibody dependent cell cytotoxicity. J Immunol 1974;112(1):26-36.

(115) Ortiz De Landazuri M, Kedar E, Fahey JL. Antibody dependent cellular cytotoxicity to a syngeneic Gross virus induced lymphoma. J Natl Cancer Inst 1974;52(1):147-152.

(116) Kedar E, Aaronov A, Sulitzeanu D. Analysis of cell membrane antigens using radioiodinated, purified antibodies. I. Solubilization and preliminary fractionation of membrane antigens of cells transformed by SV 40 virus. Isr J Med Sci 1973;9(3):266-276.

(117) Kedar E, Spira G, Sulitzeanu D. Analysis of cell membrane antigens using radioiodinated, purified antibodies. II. A factor in the serum of hamsters bearing SV 40 -induced tumors which reacts with antibodies to SV 40 -transformed cell membranes. Isr J Med Sci 1973;9(3):277-283.

(118) Naor D, Morecki S, Kedar E. Differential induction and suppression of direct and indirect PFC responses to TNP conjugated to heterologous erythrocytes. Adv Exp Med Biol 1973;29:225-232.

(119) Kedar E, Aaronov A, Goldblum N, Sulitzeanu D. Purification of antibodies to membrane antigens of hamster cells transformed by sv40 and binding of the radioiodinated, purified antibodies to intact cells. Int J Cancer 1972;9(3):536-547.

(120) Bentwich Z, Weiss D, Sulitzeanu D, Kedar E, lzak G, Cohen I, et al. Antigenic Changes on the Surface of Lymphocytes from Patients with Chronic Lymphocytic Leukemia. Cancer Res 1972;32(7):1375-1383.

(121) Kedar E, Wiener M, Goldblum N, Sulitzeanu D. Antigenic relationships between cell membranes of normal and SV40 transformed hamster kidney cells. Isr J Med Sci 1971;7(1):132-143.